Serum M65 as a Biomarker for Metastatic Renal Cell Carcinoma

Yildiz, Ibrahim; Sen, Fatma; Kilic, Leyla; Keskin, Serkan; Duranyildiz, Hadiye; Bilgin, Elif; Disci, Rian; Ekenel, Meltem; Darendeliler, Emin; Bavbek, Sevil; Basaran, Mert

doi:10.1016/j.clgc.2013.01.001

Serum M65 as a Biomarker for Metastatic Renal Cell Carcinoma

Atıf İçin Kopyala

Yildiz I., Sen F., Kilic L., Keskin S., Duranyildiz D., Bilgin E., ...Daha Fazla

CLINICAL GENITOURINARY CANCER, cilt.11, sa.3, ss.290-296, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 11 Sayı: 3
Basım Tarihi: 2013
Doi Numarası: 10.1016/j.clgc.2013.01.001
Dergi Adı: CLINICAL GENITOURINARY CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.290-296
İstanbul Üniversitesi Adresli: Evet

Özet

We aimed to investigate the prognostic significance of M30 and M65 which are biomarkers of apoptotic cell death in renal cell cancer (RCC). Serum levels of M30 and M65 were analyzed in 39 consecutively enrolled patients with metastatic RCC and control subjects using enzyme-linked immunosorbent assay (ELISA) kits. We found that high serum M65 levels might predict worse outcome resulting in shorter progression-free survival in RCC.